Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-24 7:22 PM View:  | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Apr-24 | Planned Option Sale | 10,000 | $38.49 | $384,890.00 | (6%) 178.18K to 168.18K | |
| 17-Apr-24 7:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Apr-24 | Option Exercise | 10,000 | $8.11 | $81,100.00 | 6% 168.18K to 178.18K | |
| 17-Apr-24 7:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Apr-24 | Option Exercise | 10,000 | $8.11 | $81,100.00 | 6% 168.18K to 178.18K | |
| 17-Apr-24 7:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Apr-24 | Planned Option Sale | 10,000 | $38.35 | $383,500.00 | (6%) 178.18K to 168.18K | |
| 26-Mar-24 7:38 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 26-Mar-24 | Option Exercise | 11,618 | $11.20 | $130,160.00 | 7% 156.56K to 168.18K | |
| 13-Mar-24 5:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 13-Mar-24 | Planned Option Sale | 10,000 | $42.27 | $422,730.00 | (6%) 166.56K to 156.56K | |
| 13-Mar-24 5:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 13-Mar-24 | Option Exercise | 10,000 | $10.66 | $106,638.00 | 6% 156.56K to 166.56K | |
| 13-Mar-24 5:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 12-Mar-24 | Planned Option Sale | 10,000 | $41.64 | $416,370.00 | (6%) 166.56K to 156.56K | |
| 13-Mar-24 5:22 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 12-Mar-24 | Option Exercise | 10,000 | $12.07 | $120,700.00 | 6% 156.56K to 166.56K | |
| 28-Feb-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 28-Feb-24 | Sale (Planned) | 10,000 | $39.55 | $395,463.00 | (6%) 166.56K to 156.56K | |
| 28-Feb-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 28-Feb-24 | Option Exercise | 7,471 | $8.11 | $60,589.80 | 5% 159.09K to 166.56K | |
| 28-Feb-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 27-Feb-24 | Sale (Planned) | 2,529 | $39.95 | $101,023.00 | (2%) 161.62K to 159.09K | |
| 28-Feb-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 27-Feb-24 | Planned Private Option Sale | 7,471 | $39.95 | $298,437.00 | (4%) 169.09K to 161.62K | |
| 20-Feb-24 6:49 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Payment of Exercise | 20,362 | $36.10 | $735,068.00 | (3%) 697.11K to 676.74K | |
| 20-Feb-24 6:49 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Option Exercise | 37,884 | -- | -- | 6% 659.22K to 697.11K | |
| 20-Feb-24 6:59 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Payment of Exercise | 5,257 | $36.10 | $189,778.00 | (3%) 174.34K to 169.09K | |
| 20-Feb-24 6:59 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Option Exercise | 10,376 | -- | -- | 6% 163.97K to 174.34K | |
| 20-Feb-24 6:55 PM View: | Snyder Mark Howard SVP, General Counsel | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Payment of Exercise | 2,577 | $36.10 | $93,029.70 | (18%) 14.26K to 11.68K | |
| 20-Feb-24 6:53 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Payment of Exercise | 5,601 | $36.10 | $202,196.00 | (27%) 21.08K to 15.48K | |
| 20-Feb-24 6:53 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Option Exercise | 10,422 | -- | -- | 98% 10.66K to 21.08K | |
| 20-Feb-24 6:55 PM View: | Snyder Mark Howard SVP, General Counsel | Halozyme Therapeutics, Inc. (HALO) | 16-Feb-24 | Option Exercise | 4,796 | -- | -- | 51% 9.46K to 14.26K | |
| 16-Feb-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Grant | 32,781 | -- | -- | 5% 638.0K to 670.78K | |
| 16-Feb-24 5:47 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Payment of Exercise | 5,040 | $35.91 | $180,986.00 | (3%) 169.01K to 163.97K | |
| 16-Feb-24 5:47 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Option Exercise | 3,386 | -- | -- | 2% 165.62K to 169.01K | |
| 16-Feb-24 5:41 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Payment of Exercise | 686 | $35.91 | $24,634.30 | (6%) 11.35K to 10.66K | |
| 16-Feb-24 5:47 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Grant | 8,479 | -- | -- | 5% 157.14K to 165.62K | |
| 16-Feb-24 5:41 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Option Exercise | 1,254 | -- | -- | 12% 10.09K to 11.35K | |
| 16-Feb-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Payment of Exercise | 24,655 | $35.91 | $885,361.00 | (4%) 683.88K to 659.22K | |
| 16-Feb-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 15-Feb-24 | Option Exercise | 13,092 | -- | -- | 2% 670.78K to 683.88K | |
| 13-Feb-24 4:15 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Payment of Exercise | 1,477 | $35.49 | $52,418.70 | (13%) 11.57K to 10.09K | |
| 13-Feb-24 4:15 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Option Exercise | 2,502 | -- | -- | 28% 9.07K to 11.57K | |
| 13-Feb-24 4:12 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Payment of Exercise | 16,943 | $35.49 | $601,307.00 | (3%) 654.95K to 638.0K | |
| 13-Feb-24 4:12 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Option Exercise | 31,281 | -- | -- | 5% 623.67K to 654.95K | |
| 13-Feb-24 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Payment of Exercise | 2,901 | $35.49 | $102,956.00 | (2%) 160.04K to 157.14K | |
| 13-Feb-24 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 10-Feb-24 | Option Exercise | 8,133 | -- | -- | 5% 151.91K to 160.04K | |
| 18-Jan-24 4:07 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Jan-24 | Option Exercise | 10,000 | $12.07 | $120,700.00 | 7% 151.91K to 161.91K | |
| 18-Jan-24 4:07 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Jan-24 | Planned Option Sale | 10,000 | $36.00 | $360,000.00 | (6%) 161.91K to 151.91K | |
| 18-Jan-24 4:07 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Jan-24 | Option Exercise | 10,000 | $12.07 | $120,700.00 | 7% 151.91K to 161.91K | |
| 18-Jan-24 4:07 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Jan-24 | Planned Option Sale | 10,000 | $36.00 | $360,000.00 | (6%) 161.91K to 151.91K | |
| 05-Jan-24 4:04 PM View: | Snyder Mark Howard SVP, General Counsel | Halozyme Therapeutics, Inc. (HALO) | 03-Jan-24 | Option Exercise | 7,611 | -- | -- | 158% 4.81K to 12.42K | |
| 05-Jan-24 4:04 PM View: | Snyder Mark Howard SVP, General Counsel | Halozyme Therapeutics, Inc. (HALO) | 03-Jan-24 | Payment of Exercise | 2,957 | $35.78 | $105,801.00 | (24%) 12.42K to 9.46K | |
| 13-Dec-23 7:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 13-Dec-23 | Option Exercise | 10,000 | $12.07 | $120,700.00 | 7% 151.91K to 161.91K | |
| 13-Dec-23 7:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 13-Dec-23 | Planned Option Sale | 10,000 | $40.39 | $403,940.00 | (6%) 161.91K to 151.91K | |
| 13-Dec-23 7:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 12-Dec-23 | Option Exercise | 10,000 | $13.55 | $135,547.00 | 7% 151.91K to 161.91K | |
| 13-Dec-23 7:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 12-Dec-23 | Planned Option Sale | 10,000 | $39.63 | $396,322.00 | (6%) 161.91K to 151.91K | |
| 16-Nov-23 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Nov-23 | Option Exercise | 10,000 | $13.81 | $138,100.00 | 7% 151.91K to 161.91K | |
| 16-Nov-23 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Nov-23 | Planned Option Sale | 10,000 | $39.79 | $397,880.00 | (6%) 161.91K to 151.91K | |
| 16-Nov-23 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 14-Nov-23 | Option Exercise | 10,000 | $14.32 | $143,173.00 | 7% 151.91K to 161.91K | |
| 16-Nov-23 4:18 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 14-Nov-23 | Planned Option Sale | 10,000 | $39.08 | $390,790.00 | (6%) 161.91K to 151.91K | |
| 17-Oct-23 7:28 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Oct-23 | Planned Option Sale | 10,000 | $36.52 | $365,200.00 | (6%) 161.91K to 151.91K |
